Here's Why You Should Add PacBio Stock to Your Portfolio Now

PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.

Zacks Investment Research • Jun 3, 2026

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

Zacks Investment Research • Jun 2, 2026

PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology

PACB expands HiFi sequencing reach with commercial availability of SPRQ-Nx for Revio, lowering costs by about 30% and adding AI and epigenetics upgrades.

Zacks Investment Research • Jun 1, 2026

PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing

New Revio multi-use SMRT Cells reduce sequencing costs by 30% compared to previous SPRQ chemistry while DeepConsensus improvements and expanded methylation calling increase accuracy, yield, and epigenetic insight New Revio multi-use SMRT Cells reduce sequencing costs by 30% compared to previous SPRQ chemistry while DeepConsensus improvements and expanded methylation calling increase accuracy, yield, and epigenetic insight

GlobeNewsWire • May 26, 2026

PacBio to Participate in the Jefferies Global Healthcare Conference

MENLO PARK, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at the Jefferies' Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York, New York.

GlobeNewsWire • May 21, 2026

PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology

PacBio teams with Blank Bio after its $7.2M seed round, using HiFi long reads to build RNA AI models from patient tumor samples.

Zacks Investment Research • May 20, 2026

Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology

SAN FRANCISCO--(BUSINESS WIRE)--Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology.

Business Wire • May 19, 2026

HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss

Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers

GlobeNewsWire • May 11, 2026

Pacific Biosciences of California Q1 Earnings Call Highlights

Pacific Biosciences of California NASDAQ: PACB reported first-quarter 2026 revenue of $37.2 million, roughly flat year over year, as record consumables revenue offset weaker-than-expected instrument performance amid ongoing pressure in academic and government funding, particularly in the U.S.

MarketBeat • May 8, 2026

Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript

Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026